

Supplemental Table 4: Allele Frequencies by Study: among Caucasian cases and controls

SNP	Study	GENOTYPE	CONTROLS (n)	CNTL_		CASE_	
				CONTROLS (%)	CASES (n)	CASES (%)	
<b>rs2736100</b>	<b>NCI</b>	TT	96	25	70	21.74	
		GT	181	47.14	152	47.2	
		GG	107	27.86	100	31.06	
		GT+GG	288	75	252	78.26	
	<b>NIOSH</b>	TT	127	23.61	59	19.67	
		GT	280	52.04	151	50.33	
		GG	131	24.35	90	30	
		GT+GG	411	76.39	241	80.33	
	<b>AHS</b>	TT	9	25.71	2	11.11	
		GT	20	57.14	13	72.22	
		GG	6	17.14	3	16.67	
		GT+GG	26	74.29	16	88.89	
	<b>ATBC</b>	TT	339	26.71	11	29.73	
		GT	626	49.33	18	48.65	
		GG	304	23.96	8	21.62	
		GT+GG	930	73.29	26	70.27	
	<b>PLCO</b>	TT	218	25.53	22	16.54	
		GT	404	47.31	68	51.13	
		GG	232	27.17	43	32.33	
		GT+GG	636	74.47	111	83.46	
<b>rs4295627</b>	<b>NCI</b>						

		TT	267	69.35	182	56.52
		GT	107	27.79	123	38.2
		GG	11	2.86	17	5.28
		GT+GG	118	30.65	140	43.48
	<b>NIOSH</b>					
		TT	357	66.36	179	59.67
		GT	158	29.37	107	35.67
		GG	23	4.28	14	4.67
		GT+GG	181	33.64	121	40.33
	<b>AHS</b>					
		TT	23	65.71	17	94.44
		GT	12	34.29	1	5.56
		GT+GG	12	34.29	1	5.56
	<b>ATBC</b>					
		TT	794	62.52	22	59.46
		GT	410	32.28	13	35.14
		GG	66	5.2	2	5.41
		GT+GG	476	37.48	15	40.54
	<b>PLCO</b>					
		TT	584	68.3	83	62.41
		GT	248	29.01	40	30.08
		GG	23	2.69	10	7.52
		GT+GG	271	31.7	50	37.59
<b>rs4977756</b>	<b>NCI</b>					
		AA	145	37.66	107	33.23
		AG	185	48.05	151	46.89
		GG	55	14.29	64	19.88
		AG+GG	240	62.34	215	66.77
	<b>NIOSH</b>					
		AA	185	34.45	88	29.33
		AG	255	47.49	142	47.33

		GG	97	18.06	70	23.33
		AG+GG	352	65.55	212	70.67
	<b>AHS</b>					
		AA	12	34.29	7	38.89
		AG	16	45.71	7	38.89
		GG	7	20	4	22.22
		AG+GG	23	65.71	11	61.11
	<b>ATBC</b>					
		AA	462	36.41	12	32.43
		AG	604	47.6	19	51.35
		GG	203	16	6	16.22
		AG+GG	807	63.59	25	67.57
	<b>PLCO</b>					
		AA	308	36.02	34	25.56
		AG	400	46.78	64	48.12
		GG	147	17.19	35	26.32
		AG+GG	547	63.98	99	74.44
<b>rs498872</b>	<b>NCI</b>					
		CC	185	48.18	133	41.56
		CT	168	43.75	152	47.5
		TT	31	8.07	35	10.94
		CT+TT	199	51.82	187	58.44
	<b>NIOSH</b>					
		CC	267	49.54	137	45.67
		CT	218	40.45	126	42
		TT	54	10.02	37	12.33
		CT+TT	272	50.46	163	54.33
	<b>AHS</b>					
		CC	16	45.71	7	38.89
		CT	16	45.71	9	50
		TT	3	8.57	2	11.11

rs6010620	<b>ATBC</b>	CT+TT	19	54.29	11	61.11
		CC	569	44.84	16	43.24
		CT	565	44.52	17	45.95
		TT	135	10.64	4	10.81
	<b>PLCO</b>	CT+TT	700	55.16	21	56.76
		CC	390	45.61	70	52.63
		CT	374	43.74	55	41.35
		TT	91	10.64	8	6.02
	<b>NCI</b>	CT+TT	465	54.39	63	47.37
		AA	20	5.19	11	3.42
		AG	134	34.81	93	28.88
		GG	231	60	218	67.7
	<b>NIOSH</b>	AG+GG	365	94.81	311	96.58
		AA	25	4.64	12	4
		AG	175	32.47	106	35.33
		GG	339	62.89	182	60.67
	<b>AHS</b>	AG+GG	514	95.36	288	96
		AA	1	2.86	2	11.11
		AG	8	22.86	6	33.33
		GG	26	74.29	10	55.56
<b>ATBC</b>	AG+GG	34	97.14	16	88.89	
	AA	51	4.02	1	2.7	
	AG	374	29.47	11	29.73	
	GG	844	66.51	25	67.57	
		AG+GG	1218	95.98	36	97.3

**PLCO**

AA	51	5.96	.	.
AG	323	37.78	29	21.8
GG	481	56.26	104	78.2
AG+GG	804	94.04	133	100

NCI=National Cancer Institute glioma case-control study.

NIOSH=National Institute of Occupational Safety and Health glioma case-control study.

PLCO= Glioma cases and controls identified from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

ATBC= Glioma cases and controls identified from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.

AHS= Glioma cases and controls identified from the Agricultural Health Study.